A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients
Latest Information Update: 13 Jun 2025
At a glance
- Drugs HH-CYH33 (Primary)
- Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical
Most Recent Events
- 30 Apr 2025 Results evaluating Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 22 Apr 2025 Status changed from recruiting to completed.
- 04 Jan 2023 Planned End Date changed from 20 Aug 2021 to 31 Mar 2024.